exudative Age-Related Macular Degeneration
Conditions
Interventions
None listed
Sponsors
Graduate School of Medicine and Faculty of Medicine, The University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with exudative AMD requiring treatment and age-matched control subjects at the Ophthalmology at the Tokyo University Hospital between Feb and Oct 2014 were recruited to the study. All patients with exudative AMD who are refractory to the injections of ranibizumab had been followed up for at least 12 months after the first injections of aflibercept treatment. Control subjects were collected from subjects presenting for postoperative follow up examinations for cataract, epiretinal membrane, macular hole and nonspecific ocular complaints.
Exclusion criteria
Exclusion criteria: Patients with glaucoma using eye drops for intraocular pressure (IOP) lowering and/or on systemic medications such as cholinergic, adrenergic or angiotensin II receptor blocker drugs were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess autonomic function about sympathetic and parasympathetic, a standardized heart rate variability (HRV) analysis method , by using standard autonomic function tests was used to calculate the indexes for autonomic activities; low to high frequency power (LF/HF) for sympathetic tone and the coefficient of component variance in high frequency (CCVHF) for parasympathetic tone, and the reactive response to orthostatic challenge as their change from sitting to standing position. | — |
Countries
Japan
Contacts
Public ContactYasuo Yanagi
Graduate School of Medicine and Faculty of Medicine, The University of Tokyo Department of Ophthalmology
Outcome results
None listed